P1611: INSIGHTS INTO FACILITATED IMMUNOGLOBULIN (FSCIG) USE IN PATIENTS WITH SECONDARY IMMUNODEFICIENCY DISEASES: FINAL RESULTS FROM THE FIGARO STUDY

• M. Dimou,
• M. Speletas,
• C. Milito,
• D. Huscher,
• M. Kamieniak,
• D. Pittrow,
• M. Borte

Affiliations

M. Dimou

1 First Department of Propaedeutic Internal Medicine, National & Kapodistrian University of Athens Medical School, General Hospital “LAIKO”, Athens

M. Speletas

2 School of Health Sciences Faculty of Medicine, Department of Immunology and Histocompatibility, Medical School Campus - University of Thessaly, Thessaly, Greece

C. Milito

3 Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy

D. Huscher

4 Institute of Biometry and Clinical Epidemiology, Charité-Universitätsmedizin Berlin, Berlin, Germany

M. Kamieniak

5 Global Medical, Takeda Pharma Sp.z.o.o., Warsaw, Poland

D. Pittrow

6 Institute for Clinical Pharmacology, Medical Faculty, Technical University of Dresden, Dresden

M. Borte

7 Hospital for Children and Adolescents, St. Georg Hospital